Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...

A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond ...

A chemotherapy-free regimen significantly improved outcomes compared with standard therapy for newly diagnosed Ph+ acute ...

Some younger patients with B-cell acute lymphoblastic leukemia may be able to avoid total body irradiation conditioning prior ...

Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL)—the most common ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...

ALL is the most common childhood cancer, and cases are rising. Find out why this trend is paired with a remarkable 90% survival rate, and what public health action is needed next.

About one-third of families with a child undergoing treatment for acute lymphoblastic leukemia experienced catastrophic income loss during therapy, with many developing new material hardships over the ...

A study published in the NEJM looks at universal base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia. Dr Rubina Ahmed, Director of Research, Policy and Services, Blood Cancer UK, said: ...

At some point during 2 years of chemotherapy, 30% of families reported household material hardship and 31.5% had income loss ...

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today presented clinical data for CTD402, its investigational allogeneic anti-CD7 CAR ...